The trend of chemotherapy-induced peripheral neurotoxicity in ovarian cancer survivors and its impacts on daily life during and one year after treatment

Purpose: To explore the trend of progression and regression of peripheral neuropathy (PN) induced by combination of carboplatin and paclitaxel, and the impacts on daily activities. Materials and Methods: PN was evaluated by nurse-based interview and patient-reported measures in their diary. The severity of PN scaled by National Cancer Institute Common Toxicity Criteria (NCI-CTC) before each cycle of chemotherapy and at three, six, and 12 months after drug withdrawal and coded as Grade I ~ V. Results: The authors enrolled 106 eligible patients with ovarian cancer who underwent six cycles of combined chemotherapy of carboplatin plus paclitaxel. No patients showed Grade IV and V of PN and it was gradually aggravated following the dose accumulation. About 29.3% of the patients presented no PN, 64.2% Grade I, and 6.6% Grade II after the third course of chemotherapy, but increased to 36.8% of Grade I, 25.5% of Grade II, and 34.9% of Grade III after the sixth course of chemotherapy. At one-year follow-up, the rate of PN still existed with the rate of 88.5%, 57.3%, and 38.7% at three, six, and 12 months after drug withdrawal. Thirty-one patients encountered accidents, such as sharp injury (14.2%), fall (9.4%), burn (3.8%), and cold injury (1.9%). Conclusions: A significant proportion of patients with epithelial ovarian cancer treated with carboplatin plus paclitaxel suffer long term neuropathy and it affects patient's daily activities. Specialized care is necessary to provide not only during treatment, but also months to years after drugs withdrawal

Peripheral neuropathy (PN); Chemotherapy; Ovarian cancer; Impact; Follow-up.

[1] Tofthagen C.: “Patient perceptions associated with chemotherapy induced peripheral neuropathy”. Clin. J. Oncol. Nurs., 2010, 14, E22.

[2] Argyriou A.A., Polychronopoulos P., Koutras A., Xiros N., Petsas T., Argyriou K., et al.: “Clinical and electro- physiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel- based chemotherapy”. Eur. J. Cancer Care (Engl.), 2007, 16, 23.

[3] Cancer Therapy Evaluation Program: “Common Terminology Criteria for Adverse Events, Version 3.0. DCTD, NCI, NIH, DHHS. March 31, 2003”. Publish date: August 9, 2006. Availbale at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf

[4] Pignata S., De Placido S., Biamonte R., Scambia G., Di Vagno G., Colucci G., et al.: “Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxal: the Multicenter Italian trial in Ovarian cancer(MITO-4) retrospective study”. BMC Cancer, 2005, 6, 1.

[5] Argyriou A.A., Polychronopoulos P., Iconomou G., Koutras A., Kalofonos H.P., Chroni E.: “Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies”. J. Neurol., 2005, 252 1459.

[6] Ezendam N.P., Pijlman B., Bhugwandass C., Pruijt J.F., Mols F., Vos M.C., et al.: “Chemotherapy- induced peripheral neuropathy and itsimpact on health- related quality of life among ovarian cancer survivors: Results from the population-based PROFILES registry”. Gynecol. Oncol., 2014, 135, 510.

[7] Hershman D.L., Lacchetti C., Dworkin R.H., Lavoie E.M., Bleeker J., Cavaletti G., et al.: “Prevention and management of chemotherapyinduced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline”. J. Clin. Oncol., 2014, 32, 1941.